THE APEX TIMES
A new ResearchAndMarkets report estimates a global market for generative AI in clinical trials could reach $964.2 billion by 2032, listing technology providers that include NVIDIA alongside Google, Microsoft and IBM.
Generative AI in clinical trials is being positioned for a steep growth curve, according to a new industry report now being promoted through ResearchAndMarkets and circulated by Yahoo Finance. The report, titled “Generative AI in Clinical Trials - Global Strategic Business Report 2026,” projects that the global market could expand to $964.2 billion by 2032.
The announcement does not describe any specific clinical trials or partnerships, but it frames the opportunity around broader adoption of generative AI tools across drug development and related research. In the report’s promotional material, vendors and platforms associated with generative AI are highlighted, including Google, Microsoft, NVIDIA and IBM.
For NVIDIA, the relevance is tied primarily to its role in the AI compute ecosystem. The report’s positioning suggests that buyers looking to deploy generative AI in regulated, data-heavy environments may evaluate the infrastructure and software stack behind large-scale AI applications.
While the promotional summary flags NVIDIA among the companies covered, the material provided here does not specify which NVIDIA offerings are discussed, such as particular AI platforms, deployment tools, or collaboration programs. It also does not indicate whether NVIDIA is mentioned as a provider of hardware acceleration, AI software, cloud services, or a mix of these.
The announcement also does not provide a breakdown of how generative AI is expected to be used in clinical trial workflows. It does not, for example, detail whether the market growth is attributed to patient recruitment automation, protocol design, clinical documentation, summarization of medical literature, trial operations, or other use cases.
Sector context matters because clinical research is increasingly data intensive and time constrained. Sponsors and contract research organizations face long timelines and high costs, and the promise of generative AI is often that it can reduce manual effort around documentation and information synthesis. However, adoption in healthcare and life sciences also depends on governance, data privacy, and validation requirements, areas the announcement does not address.
A key caveat is that the provided material is promotional and does not include evidence such as customer case studies, quantified adoption rates, regulatory approvals, or financial guidance from NVIDIA. Without additional disclosures, it is not possible to determine how much of the forecasted market is attributable to NVIDIA’s products or what specific commercial engagements, if any, the report is referencing.
Going forward, what to watch is whether companies named in the report move from market sizing language to concrete, auditable deployments. Investors and industry observers will likely look for public customer references, details on validated AI systems in trial settings, and clearer descriptions of how compute and AI tooling are being integrated into clinical operations. In the near term, the forecast itself may drive attention, but the commercial trail will depend on follow-through beyond the report promotion.
An investor letter tied to the RiverPark Large Growth Fund argued for keeping Microsoft in a long-duration growth portfolio, according to a report published by Yahoo Finance.
A new filing profile had suggested Bill Ackman was reducing Microsoft exposure, but Ackman says a second move involving options means the apparent sell-off outlines something different.
Among 460 large fund managers that reported positions for the quarter ended Sept. 30, 27 increased their stake in Broadcom while 27 reduced it, according to 13F filing tallies summarized by Yahoo Finance.
The Pershing Square founder says the company’s board is failing shareholders, arguing its handling of CEO Jensen Huang’s departure has raised questions beyond the firing itself.
A report says Lisa Su cashed out about $35 million as AMD trades roughly 19% below its peak, reviving the question investors often ask when insiders sell. The company has not disclosed new details in the reporting cited here, leaving some context to be filled by regulatory filings.
An investor note from RiverPark Advisors argues that Apple’s expanding services business, paired with its large installed base of devices, provides a more durable earnings engine than hardware alone.
A Yahoo Finance segment discussing a Hunterbrook investigation says AMD continued to provide firmware updates to a Chinese server vendor that U.S. authorities have blacklisted, potentially raising questions about export controls and compliance oversight.
A dispute over UK surveillance powers has ended with ministers acknowledging that they sought a “backdoor” into user data from Apple, according to a report.
A new market-focused assessment argues that while Nvidia remains the centerpiece of the AI trade, competition and capital spending from a rival in the Magnificent Seven could shape performance over the next five years.
The short seller says AMD’s exposure to Chinese customers or partners could face headwinds if U.S. export rules tighten further, while AMD did not comment in the report.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...